Drugs / Levothyroxine
Levothyroxine
also known as
LT4 · Levothyroxine Sodium · L-thyroxine · levothyroxin · Synthroid · Euthyrox · Eltroxin · Tirosint-SOL · +43 more
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | LEVOLET | — | 2022-08-05 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | THYRO-TABS | — | 2016-05-19 – 2022-04-14 | fda.gov ↗ |
| Label expansion | US (FDA) | EUTHYROX | — | 2018-09-14 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | LEVO-T | — | 2004-06-23 – 2011-03-09 | fda.gov ↗ |
| Label expansion | US (FDA) | UNITHROID | — | 2004-12-13 | fda.gov ↗ |
| Approved | US (FDA) | UNITHROID | — | 2000-08-21 | fda.gov ↗ |
Trials 84 · started per year
today
US approved 2000
6
2
1
4
3
1
1
2
4
3
4
6
7
4
4
1
4
3
4
4
1
7
6
2
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07011953 | Jul 2025 → Jul 2027 expected | schizophrenia | Peking University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT03102177 | May 2011 → Nov 2013 | hypothyroidism | Georgetown University | Completed | No outcome recorded |
| Phase 112 trials · 1 met primary | ||||||
| Phase 1 | NCT06625814 | Jul → Aug 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06428097 | Mar 2024 → Mar 2027 expected | disease related to solid organ transplantation, heart failure | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 1 | NCT03979274 | Dec 2019 → Jan 2020 | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | Met primary |
| Phase 1 | NCT03856970 | Mar → Jun 2019 | — | Ironwood Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02920385 | Oct 2016 → Apr 2017 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02332031 | Feb → Jun 2015 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT00648882 | Mar → Apr 2007 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648700 | Aug → Sep 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT01465633 | Aug → Nov 2003 | — | Heidelberg University | Completed | No outcome recorded |
| Phase 1 | NCT01465646 | Jun → Dec 2003 | — | Heidelberg University | Completed | No outcome recorded |
| Phase 1 | NCT00647855 | May → Jun 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648557 | Jan → Mar 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06790589 | Dec 2026 → Dec 2027 expected | differentiated thyroid carcinoma | AHS Cancer Control Alberta | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05823012 | May 2023 → Feb 2024 | hypothyroidism | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04782856 | Oct 2020 → Apr 2023 | goiter, hypothyroidism, thyroid cancer | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 2 | NCT03281083 | Mar 2014 → Jul 2016 | NAFLD1, type 2 diabetes mellitus | Duke-NUS Graduate Medical School | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01916304 | Jul 2013 → Jun 2014 | hypothyroidism | Takeda | Completed | No outcome recorded |
| Phase 2/38 trials · 2 missed | ||||||
| Phase 2/3 | NCT06731764 | Dec 2024 → Dec 2027 expected | hypothyroidism | UConn Health | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06345339 | Apr 2024 → Sep 2027 expected | hypothyroidism | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03053115 | Mar 2017 → Sep 2021 | hypothyroidism | Azienda USL Modena | Completed | No outcome recorded |
| Phase 2/3 | NCT02548715 | Jul 2015 → Jul 2017 | hypothyroidism, neoplasm | University of Alberta | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01950260 | Sep 2013 → Apr 2017 | Graves disease | Mayo Clinic | Completed | Missed primary |
| Phase 2/3 | NCT02090907 | May 2013 → Feb 2014 | hypothyroidism | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00921050 | Jun 2009 → Mar 2012 | hypothyroidism | Autonomous University of Nuevo León | Completed | No outcome recorded |
| Phase 2/3 | NCT01528839 | Mar 2004 → May 2008 | bipolar disorder | Charite University, Berlin, Germany | Completed | Missed primary |
| Phase 37 trials · 2 missed | ||||||
| Phase 3 | NCT07239674 | Nov 2025 → Nov 2027 expected | differentiated thyroid carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07332273 | Nov 2025 → Nov 2026 expected | obesity disorder | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Recruiting | No outcome recorded |
| Phase 3 | NCT06999278 | Jun 2025 → Apr 2027 expected | habitual spontaneous abortion | Women's Hospital School Of Medicine Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05316922 | Dec 2021 → Sep 2029 expected | hypothyroidism | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Recruiting | No outcome recorded |
| Phase 3 | NCT01576705 | Apr 2012 → Dec 2017 | Down syndrome | Jerome Lejeune Institute | Completed | Missed primary |
| Phase 3 | NCT00388297 | Oct 2006 → Aug 2015 | hypothyroidism, pregnancy disorder | The George Washington University Biostatistics Center | Completed | Missed primary |
| Phase 3 | NCT01306227 | Sep 2006 → Dec 2014 | thyroid gland disorder | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 427 trials · 2 met primary · 4 missed | ||||||
| Phase 4 | NCT06073665 | Jan 2024 → Apr 2028 expected | hypothyroidism | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 4 | NCT06135948 | Mar → Jun 2022 | thyroid hormone metabolism, abnormal | Emirates Health Services (EHS) | Completed | No outcome recorded |
| Phase 4 | NCT05228184 | Jan 2022 → Mar 2025 | congenital hypothyroidism | IBSA Institut Biochimique SA | Terminated | Met primary Stop: Enrollment |
| Phase 4 | NCT04878614 | May 2021 → Feb 2022 | hypothyroidism | University of California, Los Angeles | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04747275 | Jan → Nov 2021 | hypothyroidism, trisomy 21 | Children's Mercy Hospital Kansas City | Terminated | No outcome recorded |
| Phase 4 | NCT04132622 | Jan 2020 → Dec 2022 | paraquat poisoning | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04953195 | Jan 2019 → Sep 2021 | hypothyroidism | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03094416 | Jul 2018 → Jun 2020 | postsurgical hypothyroidism | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 4 | NCT03096613 | Apr 2017 → Feb 2019 | hypothyroidism, systolic heart failure | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | Met primary |
| Phase 4 | NCT02946918 | Feb 2017 → Nov 2019 | postsurgical hypothyroidism, thyroid cancer | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT02832934 | Jun → Dec 2016 | atherosclerosis, heart failure, thyroid gland disorder | Insel Gruppe AG, University Hospital Bern | Completed | Missed primary |
| Phase 4 | NCT02832960 | Jun → Dec 2016 | atherosclerosis, heart failure, thyroid gland disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT02917863 | May 2016 → May 2018 | hypothyroidism | Meyer Children's Hospital IRCCS | Unknown | No outcome recorded |
| Phase 4 | NCT02577367 | Oct 2015 → Apr 2020 | hypothyroidism | Jocelyne Karam | Withdrawn | No outcome recorded |
| Phase 4 | NCT02186405 | Oct 2015 → Oct 2016 | hypothyroidism | Centre Hospitalier Universitaire de Nice | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02512978 | Aug 2015 → Dec 2018 | hypothyroidism, myocardial infarction | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02329379 | May → Dec 2015 | goiter | Sheng-Chiang Su | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02316743 | Dec 2014 → Jun 2015 | hypothyroidism, systolic heart failure | University of Sherbrooke | Unknown | No outcome recorded |
| Phase 4 | NCT04354896 | May 2014 → May 2018 | hypothyroidism, muscular atrophy | Insel Gruppe AG, University Hospital Bern | Completed | Missed primary |
| Phase 4 | NCT02500342 | Jan 2014 → Apr 2018 | thyroid gland disorder | Insel Gruppe AG, University Hospital Bern | Completed | Missed primary |
| Phase 4 | NCT02491008 | Jan 2014 → Dec 2016 | disease of bone structure, osteoporosis, thyroid gland disorder | Insel Gruppe AG, University Hospital Bern | Completed | Missed primary |
| Phase 4 | NCT01853579 | Mar 2013 → Apr 2018 | depressive disorder, hypothyroidism | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT01647750 | Aug 2012 → Aug 2014 | hypothyroidism | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT01631305 | Jan 2012 → Dec 2013 | euthyroid sick syndrome | Sinaloa Pediatric Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01379170 | Jun 2011 → Dec 2014 | hypothyroidism, type 2 diabetes mellitus | Maastricht University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00565864 | Aug 2008 → Aug 2013 | hypothyroidism | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT00150124 | Jan 2003 → Dec 2008 | Graves disease, toxic multinodular goitre | Steen Bonnema | Completed | No outcome recorded |
| Phase not applicable23 trials · 1 missed | ||||||
| — | NCT07625722 | Jun 2026 → Jun 2027 expected | fetal growth restriction, neurodevelopmental disorder, thyroid hormone metabolism, abnormal | Shandong Provincial Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06971965 | Jun 2025 → Dec 2027 expected | thyroid gland papillary carcinoma | National Cancer Center, Korea | Not yet recruiting | No outcome recorded |
| — | NCT07393165 | May 2025 → May 2026 overdue | hypothyroidism | Tanta University | Recruiting | No outcome recorded |
| — | NCT06652113 | Nov 2024 → Mar 2035 expected | autoimmune thyroid disease, pregnancy loss, recurrent, 4 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT07421869 | Jun 2024 → Mar 2029 expected | hypothyroidism | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT05240911 | Jun 2022 → Feb 2023 | hypothyroidism, thyroid tumor | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT07380854 | Feb 2022 → Feb 2032 expected | hypothyroidism | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT06041204 | May 2021 → May 2026 overdue | female infertility, hypothyroidism, polycystic ovary syndrome | Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy | Recruiting | No outcome recorded |
| — | NCT03977207 | Jul 2020 → Nov 2025 overdue | hypothyroidism | University of California, Irvine | Recruiting | No outcome recorded |
| — | NCT03606824 | Mar 2019 → Feb 2020 | atherosclerotic cardiovascular disease, hyperlipidemia, hypothyroidism | Shaochun.Li | Unknown | No outcome recorded |
| — | NCT03191188 | Jul 2017 → Jul 2021 | chronic kidney disease, thyroid gland disorder | University of California, Irvine | Unknown | No outcome recorded |
| — | NCT02399475 | Jan 2015 → Sep 2019 | hypothyroidism | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT02374593 | Mar 2014 → May 2016 | congenital hypothyroidism | Indiana University | Completed | No outcome recorded |
| — | NCT03115515 | Aug 2011 → Feb 2018 | pregnancy disorder, thyroid gland disorder | Medstar Health Research Institute | Completed | Missed primary |
| — | NCT01280292 | Feb 2011 → Feb 2013 | hypothyroidism | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT04528797 | Sep 2010 → Aug 2012 | — | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00770016 | Jan 2010 | hypothyroidism | University of Aarhus | Terminated | No outcome recorded |
| — | NCT00552253 | Oct 2007 → Jul 2008 | nodular goiter | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT01189344 | Sep 2007 → Jul 2010 | morbid obesity | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT00403390 | Nov 2006 → Dec 2009 | congenital hypothyroidism | Boston Children's Hospital | Completed | No outcome recorded |
| — | NCT00488644 | Feb 2006 → Mar 2010 | brain neoplasm, hypothyroidism | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00524238 | Mar 2004 → Aug 2006 | hypothyroidism | University of Aarhus | Completed | No outcome recorded |
| — | NCT00498238 | Jul 2003 → Sep 2005 | hypothyroidism | Assaf-Harofeh Medical Center | Completed | No outcome recorded |
| Comparator or background therapy43 trials | ||||||
| Phase 0 | NCT06373523 Background | Sep 2024 → Jun 2025 overdue | NAFLD1, fibrotic liver disease | Post Graduate Institute of Medical Education and Research, Chandigarh | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT03106935 Comparator | Jul 2015 → Dec 2017 | pregnancy loss, recurrent, 4 | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 1 | NCT04868045 Background | Apr 2021 → Feb 2023 | thyroid cancer | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01557504 Background | Jul 2012 → Apr 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00535561 Comparator | Jun → Sep 2007 | hypothyroidism, iron deficiency anemia | Duzce University | Completed | No outcome recorded |
| Phase 1/2 | NCT04178928 Comparator | Jan 2020 → Jan 2021 | hypothyroidism | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03098433 Comparator | Oct 2017 → Jun 2019 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 2 | NCT07424183 Background | Jun 2026 → Jun 2027 expected | hypothyroidism | University of Pennsylvania | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05526144 Comparator | Apr 2023 → Dec 2029 expected | fibrotic liver disease, metabolic dysfunction-associated steatohepatitis | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2 | NCT05712421 Comparator | Feb 2023 → May 2025 | hypothyroidism | Neuvosyn Laboratories, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05412979 Comparator | Apr 2022 → Oct 2023 | hypothyroidism | Sention Therapeutics, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04124705 Comparator | Oct 2019 → Jun 2021 | hypothyroidism | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT03627611 Comparator | Aug 2018 → Jun 2020 | hypothyroidism | Oslo University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01391962 Background | Jul 2011 → Nov 2023 | alveolar soft part sarcoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00106119 Comparator | Mar 2005 → Nov 2013 | thyroid gland disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT06660823 Comparator | Nov 2024 → Jun 2025 | euthyroid sick syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT06276205 Background | Mar 2024 → Jan 2025 | hyperlipidemia, hypothyroidism, lip disorder | King Edward Medical University | Completed | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06036576 Comparator | Mar 2022 → May 2023 | pregnancy loss, recurrent, 4, thyroid gland disorder | Al-Kindy College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03898622 Comparator | Oct 2018 → Jan 2019 | chronic kidney disease, hypothyroidism | Hospital Civil de Guadalajara | Completed | No outcome recorded |
| Phase 3 | NCT03391154 Comparator | May 2017 → Aug 2020 | thyroid hormone metabolism, abnormal | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT01486667 Comparator | Oct 2011 → Oct 2013 | hyperlipidemia | King Saud University | Unknown | No outcome recorded |
| Phase 4 | NCT06653907 Comparator | Oct 2024 → Dec 2026 expected | pregnancy disorder with abortive outcome, thyroid gland disorder | Yang Zhang | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04288115 Comparator | Mar 2021 → Oct 2022 | hypothyroidism | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT06641440 Background | Jan 2018 → Dec 2023 | pregnancy loss, recurrent, 4 | Centre for Endocrinology and Reproductive Medicine, Italy | Completed | No outcome recorded |
| Phase 4 | NCT02211053 Comparator | Jul 2014 → Dec 2016 | — | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01660126 Comparator | May 2014 → Nov 2016 | hypothyroidism | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 4 | NCT01848171 Comparator | Jul 2013 → Jul 2023 | hypothyroidism | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01831869 Comparator | Apr 2013 → Apr 2022 | hypothyroidism | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05371262 Comparator | May 2011 → May 2018 | congenital hypothyroidism | Federico II University | Completed | No outcome recorded |
| Phase 4 | NCT01276782 Comparator | Jan → Jun 2011 | systemic lupus erythematosus | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00206375 Background | May 2003 → Sep 2011 | hypothyroidism | Baylor College of Medicine | Terminated | No outcome recorded |
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT06353555 Comparator | Oct 2023 → Jun 2025 | euthyroid sick syndrome, intracerebral hemorrhage | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT04600349 Comparator | Feb → Dec 2020 | Hashimoto thyroiditis | University of Bucharest | Completed | No outcome recorded |
| — | NCT04472988 Background | Jan → Dec 2020 | Hashimoto thyroiditis | University of Bucharest | Completed | No outcome recorded |
| — | NCT03024151 Comparator | Dec 2016 → Nov 2017 | anxiety, depressive disorder, thyroid cancer | Inje University | Completed | No outcome recorded |
| — | NCT02317926 Comparator | May 2015 → May 2018 | hypothyroidism | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| — | NCT03095963 Comparator | Jan 2014 → Oct 2016 | hypothyroidism | Azienda USL Modena | Completed | No outcome recorded |
| — | NCT01832753 Comparator | Jan 2013 → Oct 2017 | Down syndrome, hypothyroidism | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| — | NCT01739972 Comparator | May 2012 → May 2014 | peripheral hypothyroidism | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| — | NCT00230802 Comparator | Jul 2005 → Jul 2010 | hypothyroidism, pregnancy disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT00846755 Comparator | Mar 2005 → Mar 2008 | pregnancy disorder, thyroid gland disorder | Ospedale V. Fazzi | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
All press releases naming this drug 16 releases
Evidence & citations 55 cited values
Every value below carries the sentence it was read from. 133 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levothyroxine | “Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to...” NCT01557504 ↗96“Prospective, Single Dose, Randomized, Open Label, Comparative, Cross-study to Establish Bioequivalence Between the New Formulation and the Approved Formulation for...” NCT03979274 ↗ “Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.” NCT05894954 ↗ “the study aim to detect the effect of low dose levothyroxine 50 ug on pregnant females and compare it with others receiving placebo” NCT03391154 ↗ “The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)” NCT04600349 ↗ “The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)” NCT04472988 ↗ “while on a continuous block-replacement regimen (+BRT, n = 48, median dose 15 mg methimazole and 100 μg levothyroxine)” PMID 21175612 ↗ Dec 2010 “The relationship between probiotics and levothyroxine (LT4) requirement has not yet been investigated.” PMID 29184537 ↗ Nov 2017 “The intervention will start with Levothyroxine 50 mcg daily with regular blinded dosis titration.” NCT04354896 ↗ “despite adequate levels of TSH after starting levothyroxine (LT4) therapy” PMID 35572853 ↗ May 2022 “75 micrograms of levothyroxine only daily for three months” NCT06641440 ↗ |
| Known as | Eferox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Eltroxin | “The patients were treated with levothyroxine (Eltroxin, Glaxo) at a starting dose of 50 mcg per day.” NCT00498238 ↗ |
| Known as | Eltroxin (Levothyroxin, GlaxoSmithKline Pharma) | “Eltroxin (Levothyroxin, GlaxoSmithKline Pharma)” NCT00770016 ↗ |
| Known as | eltroxin 50 | “will receive 50 ug of levothyroxine (eltroxin 50) aspen,Egypt throughout the pregnancy” NCT03391154 ↗ |
| Known as | Ermeza | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Euthyrox | “Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above.” NCT06652113 ↗3“Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks.” NCT07011953 ↗ |
| Known as | Euthyrox/levothyroxine | “Euthyrox/levothyroxine” NCT01379170 ↗ |
| Known as | Eutirox | “Prospective, Single Dose, Randomized, Open Label, Comparative, Cross-study to Establish Bioequivalence Between the New Formulation and the Approved Formulation for...” NCT03979274 ↗ |
| Known as | Evotrox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | L-thyroxine | “Patients were randomly assigned to one of four treatments: placebo, folinic acid (FA), L-thyroxine, or FA+L-thyroxine, administered for 12 months.” PMID 31281181 ↗ Jul 201910“patients who received an increased dose of L-thyroxine, 25 mcg, n = 50” NCT06135948 ↗ |
| Known as | L-Thyroxine Christiaens | “Levothyroxine (L-Thyroxine Christiaens®) is used in the treatment of hypothyroidism.” NCT01916304 ↗ |
| Known as | L-thyroxine henning | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levaxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levo-t | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levolet | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothroid | “Levothroid® Tablets 300 μg” NCT00648700 ↗ |
| Known as | Levothyrox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | levothyroxin | “Drug: levothyroxin” NCT03391154 ↗ |
| Known as | Levothyroxine sodique | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothyroxine Sodium | “Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above.” NCT06652113 ↗17“Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks.” NCT07011953 ↗ “Levothyroxine sodium new formulation” NCT01916304 ↗ “Levothyroxine Sodium Tablets 300 μg” NCT00648700 ↗ “Levothyroxine Sodium (LT4) Tablets” NCT07424183 ↗ “Levothyroxine Sodium (LT4) Tablets” NCT06653907 ↗ “Drug: Levothyroxine Sodium” NCT03977207 ↗ “Drug: Levothyroxine Sodium” NCT03281083 ↗ “Drug: levothyroxine sodium” NCT00921050 ↗ “Drug: Levothyroxine Sodium” NCT03191188 ↗ “Drug: Levothyroxine Sodium” NCT05228184 ↗ |
| Known as | Levothyroxine sodium anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothyroxine sodium hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothyroxine sodium pentahydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothyroxine Sodium Tablets | “Drug: Levothyroxine Sodium Tablets” NCT04953195 ↗ |
| Known as | Levothyroxinum natricum anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levotiroxina de sodio | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levoxyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Liotrix (t4) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | LT4 | “Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (\>3.0-5.0 and...” NCT03977207 ↗19“A recent trial showed that 1:3 μg:μg liothyronine (L-T3) substitution for levothyroxine (L-T4) achieving near-identical TSH levels resulted in a significant decrease in weight...” PMID 23585666 ↗ Apr 2013 “We report a randomized, multicenter, open-label trial (ClinicalTrials.gov: NCT03096613) to investigate the clinical benefits of levothyroxine (L-T4) administration in...” PMID 38537636 ↗ Mar 2024 “The effect of levothyroxine (LT4) therapy for subclinical hypothyroidism (SHypo) on appendicular bone geometry and volumetric density has so far not been studied.” PMID 35381390 ↗ Apr 2022 “To evaluate the effect of levothyroxine (LT4) replacement therapy on nonalcoholic fatty liver disease (NAFLD) in subclinical hypothyroidism (SCH) patients.” PMID 28473851 ↗ Apr 2017 “Treatment with proton pump inhibitors (PPIs) and antacids affects the gastrointestinal absorption of levothyroxine sodium (LT4) tablets.” PMID 37885233 ↗ Nov 2023 “Objective: To determine whether low dose levothyroxine (LT4) therapy may be a potential treatment for diabetic patients with NAFLD.” NCT03281083 ↗ “Levothyroxine (LT4) is widely used for hypothyroidism; evaluating its adjuvant role in obesity management is clinically relevant.” NCT07332273 ↗ “The intervention group will receive oral levothyroxine (L-T4) initiated on postnatal day 14 at a starting dose of 8 ug/kg/day.” NCT07625722 ↗ “Levothyroxine sodium (LT4) is an effective drug prescribed as replacement therapy for patients with hypothyroidism” NCT01189344 ↗ “The relationship between probiotics and levothyroxine (LT4) requirement has not yet been investigated.” PMID 29184537 ↗ Nov 2017 |
| Known as | Monosodium l-thyroxine hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Novothyrox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | NSC-259940 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | NSC-36397 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Oroxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | SK&F 1-6528 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Sodium levothyroxine pentahydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Soloxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Synthetic levothyroxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Synthroid | “Levothyroxine Oral Tablet [Synthroid]” NCT06790589 ↗5“Brand Name Levothyroxine (Synthroid)” NCT00403390 ↗ “Growth hormone + Synthroid + Lupron” NCT00206375 ↗ “Abbott's Synthroid® 200 μg tablets” NCT00648557 ↗ |
| Known as | T4 (liotrix) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyquidity | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyro-tabs | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine, i-125 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine, i-131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine, l- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Tirosint | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Tirosint-SOL | “Tirosint®-SOL (levothyroxine sodium) oral solution (IBSA Pharma Inc.)” NCT05228184 ↗1“Liquid stable levothyroxine (L-T4) Tirosint-SOL” NCT04747275 ↗ |
| Known as | Unithroid | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Action | Restore | “thyroid hormone replacement” NCT00388297 ↗ |
| Modality | Other / unclassified | “thyroid hormone replacement” NCT04354896 ↗ |
| Route | Oral | “75 mcg by mouth (PO) Daily for 8 Weeks” NCT00488644 ↗ |